Replies to post #82 on Aquestive Therapeutics Inc (AQST)

[DorseyE]

ADHD NDA Filing NDA submission announced March 2, 2020.
Exservan (riluzole) Oral Film Amyotrophic Lateral Sclerosis Approved FDA Approval announced November 22, 2019.
Sympazan Lennox-Gastaut Syndrome Approved Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203 Epileptic seizures PDUFA PDUFA date September 27, 2020.
AQST-119 Erectile dysfunction CRL CRL issued November 16, 2018.
APL-130277 Parkinson’s Disease with motor fluctuations PDUFA CRL issued January 30, 2019 through partner Sunovion (private company). NDA refiled. New PDUFA date May 21, 2020.
AQST-108 Anaphylaxis Phase 1 Pivotal pharmacokinetic (PK) trials to be initiated before the end of 2020

Simplified version, click on link...
https://www.biopharmcatalyst.com/company/AQST
Be sure to CLICK ON DRUG INFORMATION